IL6R and neoplasm: By utilizing peptides, such as pepL, that bind to receptors upregulated in tumor cells, such as IL-6Rα, researchers aim to directly target the cytokine to tumor tissue and enhance the bioactivity of IL-27 (Figueiredo et al., 2021).